Abstract 5374
Background
We aimed to validate the prognostic effects of the metastatic lymph nodes ratio (LNR) in patients with gastric neuroendocrine tumour (G-NET), and establish a nomogram to predict the survival of patients.
Methods
A total of 315 patients with G-NET in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015 were included. Pearson correlation and Cox regression were performed to identify the association between LNR and survival. Nomograms were adopted to predict overall survival (OS) and cancer-specific survival (CSS).
Results
LNR has a negative correlation with OS and CSS (Pearson correlation coefficients: 0.343, P < 0.001; 0.389, P < 0.001, respectively). The multivariate analyses indicated age, tumour site, differentiation, T staging, M staging, chemotherapy and LNR were independent prognostic factors for both OS and CSS. The concordance index (C-index) of the nomograms for OS and CSS were superior to those of the TNM classification (0.773 vs. 0.731; 0.807 vs. 0.769, respectively). According to the area under the ROC curve (AUC), the predictive ability of the new nomogram for 3- and 5-year OS was better than TNM classification (0.908 vs. 0.846, P = 0.004; 0.899 vs. 0.827, P < 0.001, respectively). And the predictive ability of the new nomogram for 1-, 3- and 5-year CSS was better than TNM classification (0.936 vs. 0.848, P = 0.007; 0.910 vs. 0.855, P = 0.003; 0.894 vs. 0.836, P = 0.001, respectively).
Conclusions
LNR was an independent predictor of OS and CSS in G-NET. The nomograms based on the LNR were superior to the TNM classification in predicting the clinical outcomes for G-NET patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Yaobin Lin.
Funding
The Fujian Province Natural Science Foundation (2017J01260), Joint Funds for the Innovation of Science and Technology, Fujian province (2017Y9074), and the Peking University Cancer Hospital & Institute, Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education/Beijing (2017 Open Project-9).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1988 - Molecular profiling reveals novel targetable biomarkers in neuroendocrine carcinoma of the uterine cervix
Presenter: Semir Vranic
Session: Poster Display session 2
Resources:
Abstract
2672 - Changes in clinico-pathological characteristics of vulvar cancer in Japan: increasing oldest-old, stage-shifting, and decreasing cohort-level survival
Presenter: Shin Nishio
Session: Poster Display session 2
Resources:
Abstract
4306 - Tumor Treating Fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: Phase 3 INNOVATE-3/ENGOT-ov50 study
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
5136 - Randomized, phase 1b/2 study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
Presenter: Susana Banerjee
Session: Poster Display session 2
Resources:
Abstract
2296 - An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: A Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION
Presenter: Jung-Yun Lee
Session: Poster Display session 2
Resources:
Abstract
2732 - A phase 2 study of pembrolizumab in combination with doxorubicin in advanced, recurrent or metastatic endometrial cancer
Presenter: Ana Oaknin
Session: Poster Display session 2
Resources:
Abstract
4404 - ENGOT-EN9/LEAP-001: a phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer
Presenter: Christian Marth
Session: Poster Display session 2
Resources:
Abstract
4564 - Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8)
Presenter: Ignace Vergote
Session: Poster Display session 2
Resources:
Abstract
4933 - Updated data of Epitopes-HPV02 trial and external validation of efficacy of DCF in prospective Epitopes-HPV01 study in advanced anal squamous cell carcinoma. Pooled analysis of 115 patients
Presenter: Stefano Kim
Session: Poster Display session 2
Resources:
Abstract
2301 - Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)
Presenter: Alexandra Gilbert
Session: Poster Display session 2
Resources:
Abstract